Arbutus Biopharma Corp (ABUS)
3.51
+0.05
(+1.45%)
USD |
NASDAQ |
Nov 22, 16:00
3.51
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Cash from Operations (Quarterly): -20.74M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -20.74M |
| June 30, 2024 | -14.50M |
| March 31, 2024 | -19.30M |
| December 31, 2023 | -17.29M |
| September 30, 2023 | -21.78M |
| June 30, 2023 | -19.56M |
| March 31, 2023 | -27.30M |
| December 31, 2022 | -16.99M |
| September 30, 2022 | -18.69M |
| June 30, 2022 | -20.29M |
| March 31, 2022 | 20.62M |
| December 31, 2021 | -19.61M |
| September 30, 2021 | -16.04M |
| June 30, 2021 | -14.01M |
| March 31, 2021 | -17.88M |
| December 31, 2020 | -15.01M |
| September 30, 2020 | -12.17M |
| June 30, 2020 | -8.801M |
| March 31, 2020 | -15.45M |
| December 31, 2019 | -13.35M |
| September 30, 2019 | -23.47M |
| June 30, 2019 | -17.60M |
| March 31, 2019 | -16.58M |
| December 31, 2018 | -17.08M |
| September 30, 2018 | -13.20M |
| Date | Value |
|---|---|
| June 30, 2018 | -17.62M |
| March 31, 2018 | -19.97M |
| December 31, 2017 | -10.34M |
| September 30, 2017 | -15.68M |
| June 30, 2017 | -5.082M |
| March 31, 2017 | -17.54M |
| December 31, 2016 | -14.82M |
| September 30, 2016 | -14.71M |
| June 30, 2016 | -16.80M |
| March 31, 2016 | -11.55M |
| December 31, 2015 | -18.21M |
| September 30, 2015 | -2.527M |
| June 30, 2015 | -17.80M |
| March 31, 2015 | -17.84M |
| December 31, 2014 | -6.846M |
| September 30, 2014 | -6.72M |
| June 30, 2014 | -8.01M |
| March 31, 2014 | 9.155M |
| December 31, 2013 | 2.567M |
| September 30, 2013 | -3.67M |
| June 30, 2013 | -2.794M |
| March 31, 2013 | -2.84M |
| December 31, 2012 | 40.36M |
| September 30, 2012 | -1.513M |
| June 30, 2012 | -1.674M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-27.30M
Minimum
Mar 2023
20.62M
Maximum
Mar 2022
-15.41M
Average
-17.14M
Median
Cash from Operations (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 221.48M |
| Amicus Therapeutics Inc | -22.97M |
| Ionis Pharmaceuticals Inc | -114.99M |
| GlycoMimetics Inc | -7.994M |
| FibroGen Inc | -8.376M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -11.99M |
| Cash from Financing (Quarterly) | 1.775M |
| Free Cash Flow | -71.92M |
| Free Cash Flow Per Share (Quarterly) | -0.1097 |
| Free Cash Flow to Equity (Quarterly) | -20.74M |
| Free Cash Flow Yield | -11.36% |